Cosmo Pharmaceuticals NV logo

COPN - Cosmo Pharmaceuticals NV Share Price

CHF91 -0.8  -0.9%

Last Trade - 10:50am

Mid Cap
Market Cap £1.04bn
Enterprise Value £1.00bn
Revenue £53.0m
Position in Universe 386th / 1045
Unlock COPN Revenue
Relative Strength (%)
1m +5.56%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.65%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
60.6 67.7 67.2 65.6 62.5 60.9 60.9 73.9 +0.1%
+31.3 -78.1
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, CosmoPharmaceuticals NV revenues decreased 2% to EUR60.9M. Netloss decreased 68% to EUR7.9M. Revenues reflect a decreasein demand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsSelling, general and administrative cost decrease of 47% toEUR18.7M (expense), Research and development costs decreaseof 10% to EUR13.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


COPN Revenue Unlock COPN Revenue

Net Income

COPN Net Income Unlock COPN Revenue

Normalised EPS

COPN Normalised EPS Unlock COPN Revenue

PE Ratio Range

COPN PE Ratio Range Unlock COPN Revenue

Dividend Yield Range

COPN Dividend Yield Range Unlock COPN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
COPN EPS Forecasts Unlock COPN Revenue
Profile Summary

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since May 18, 2016
No. of Shareholders: n/a
No. of Employees: 265
Sector Healthcare
Industry Pharmaceuticals
Exchange SIX Swiss Exchange
Shares in Issue 14,433,300
Free Float (0.0%)
Eligible for
COPN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for COPN
Upcoming Events for COPN
Friday 28th May, 2021
Cosmo Pharmaceuticals NV Annual Shareholders Meeting
Tuesday 1st June, 2021
Cosmo Pharmaceuticals NV at Jefferies Healthcare Conference (Virtual)
Friday 30th July, 2021
Half Year 2021 Cosmo Pharmaceuticals NV Earnings Release
Frequently Asked Questions for Cosmo Pharmaceuticals NV
What is the Cosmo Pharmaceuticals NV share price?

As of 10:50am, shares in Cosmo Pharmaceuticals NV are trading at CHF91, giving the company a market capitalisation of £1.04bn. This share price information is delayed by 15 minutes.

How has the Cosmo Pharmaceuticals NV share price performed this year?

Shares in Cosmo Pharmaceuticals NV are currently trading at CHF91 and the price has moved by 21.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cosmo Pharmaceuticals NV price has moved by -8.29% over the past year.

What are the analyst and broker recommendations for Cosmo Pharmaceuticals NV?

Of the analysts with advisory recommendations for Cosmo Pharmaceuticals NV, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cosmo Pharmaceuticals NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cosmo Pharmaceuticals NV next release its financial results?

Cosmo Pharmaceuticals NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Cosmo Pharmaceuticals NV dividend yield?

Cosmo Pharmaceuticals NV does not currently pay a dividend.

Does Cosmo Pharmaceuticals NV pay a dividend?

Cosmo Pharmaceuticals NV does not currently pay a dividend.

When does Cosmo Pharmaceuticals NV next pay dividends?

Cosmo Pharmaceuticals NV does not currently pay a dividend.

How do I buy Cosmo Pharmaceuticals NV shares?

To buy shares in Cosmo Pharmaceuticals NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cosmo Pharmaceuticals NV?

Shares in Cosmo Pharmaceuticals NV are currently trading at CHF91, giving the company a market capitalisation of £1.04bn.

Where are Cosmo Pharmaceuticals NV shares listed? Where are Cosmo Pharmaceuticals NV shares listed?

Here are the trading details for Cosmo Pharmaceuticals NV:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: COPN
What kind of share is Cosmo Pharmaceuticals NV?

Based on an overall assessment of its quality, value and momentum, Cosmo Pharmaceuticals NV is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cosmo Pharmaceuticals NV share price forecast 2021?

Shares in Cosmo Pharmaceuticals NV are currently priced at CHF91. At that level they are trading at 20.34% discount to the analyst consensus target price of 0.00.

Analysts covering Cosmo Pharmaceuticals NV currently have a consensus Earnings Per Share (EPS) forecast of -0.911 for the next financial year.

How can I tell whether the Cosmo Pharmaceuticals NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cosmo Pharmaceuticals NV. Over the past six months, the relative strength of its shares against the market has been -9.93%. At the current price of CHF91, shares in Cosmo Pharmaceuticals NV are trading at 7.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cosmo Pharmaceuticals NV PE Ratio?

We were not able to find PE ratio data for Cosmo Pharmaceuticals NV.

Who are the key directors of Cosmo Pharmaceuticals NV?

Cosmo Pharmaceuticals NV's management team is headed by:

Alessandro Della Cha - CEO
Dieter A. Enkelmann - NED
Maria Roncarolo - NED
Kevin Donovan - NED
Eimear Cowhey - NED
Niall Donnelly - CFO
Luigi Moro - CSO
Luisa Bartorelli - MGB
Marco Lecchi - MGB
Andrea Lovati - MGB
Davide Malavasi - MGB
Mauro Ajani - NEC
Giuseppe Cipriano - COO
Roberta Bozzella - MGB
Sean MacDonald - MGB
Who are the major shareholders of Cosmo Pharmaceuticals NV?

Here are the top five shareholders of Cosmo Pharmaceuticals NV based on the size of their shareholding:

Ajani (Mauro) Individual Investor
Percentage owned: 37.13% (5.58m shares)
Heinrich Herz AG Corporation
Percentage owned: 8.01% (1.20m shares)
Family (Hopp) Individual Investor
Percentage owned: 5.23% (786k shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 4.99% (751k shares)
UBS Asset Management (Switzerland) Investment Advisor
Percentage owned: 2.41% (362k shares)
Similar to COPN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.